Fenwick Represents Elegen in $35M Series B Financing

Fenwick represented Elegen, a developer of next-generation DNA synthesis and production, in its $35 million Series B financing. The round was led by Triatomic Capital and was joined by strategic investors GSK, John Ballantyne (co-founder of Aldervron), and existing investors.

Elegen will use the funds to accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates James Li, Tarra Theisen, and Ty Chung.